143 related articles for article (PubMed ID: 31123687)
21. Oncolytic herpes simplex virus type 1 and host immune responses.
Fukuhara H; Todo T
Curr Cancer Drug Targets; 2007 Mar; 7(2):149-55. PubMed ID: 17346106
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis.
Ghouse SM; Nguyen HM; Bommareddy PK; Guz-Montgomery K; Saha D
Front Oncol; 2020; 10():384. PubMed ID: 32266155
[TBL] [Abstract][Full Text] [Related]
23. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.
Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986
[TBL] [Abstract][Full Text] [Related]
24. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
Kahramanian A; Kuroda T; Wakimoto H
Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
[TBL] [Abstract][Full Text] [Related]
25. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
26. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
27. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
28. Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
Passaro C; Alayo Q; De Laura I; McNulty J; Grauwet K; Ito H; Bhaskaran V; Mineo M; Lawler SE; Shah K; Speranza MC; Goins W; McLaughlin E; Fernandez S; Reardon DA; Freeman GJ; Chiocca EA; Nakashima H
Clin Cancer Res; 2019 Jan; 25(1):290-299. PubMed ID: 30279232
[TBL] [Abstract][Full Text] [Related]
29. Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.
Liu X; He B
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404809
[TBL] [Abstract][Full Text] [Related]
30. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.
Lussier DM; Woolf EC; Johnson JL; Brooks KS; Blattman JN; Scheck AC
BMC Cancer; 2016 May; 16():310. PubMed ID: 27178315
[TBL] [Abstract][Full Text] [Related]
31. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
32. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
33. Immunovirotherapy for glioblastoma.
Ning J; Wakimoto H; Rabkin SD
Cell Cycle; 2014; 13(2):175-6. PubMed ID: 24241205
[No Abstract] [Full Text] [Related]
34. Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution.
Hedberg J; Studebaker A; Smith L; Chen CY; Westfall JJ; Cam M; Gross A; Hernandez-Aguirre I; Martin A; Kim D; Dhital R; Kim Y; Roberts RD; Cripe TP; Mardis ER; Cassady KA; Leonard J; Miller KE
Mol Ther Oncolytics; 2023 Sep; 30():39-55. PubMed ID: 37583388
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
36. Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells.
Hensel MT; Peng T; Cheng A; De Rosa SC; Wald A; Laing KJ; Jing L; Dong L; Magaret AS; Koelle DM
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701399
[TBL] [Abstract][Full Text] [Related]
37. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
[TBL] [Abstract][Full Text] [Related]
40. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles.
Fu X; Tao L; Wang PY; Cripe TP; Zhang X
Oncotarget; 2018 Apr; 9(30):21348-21358. PubMed ID: 29765544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
